Search

Omeros Corp

Open

SectorHealthcare

17.18 -0.81

Overview

Share price change

24h

Current

Min

16.17

Max

17.88

Key metrics

By Trading Economics

Income

-35M

51M

Sales

9.9M

9.9M

P/E

Sector Avg

11.641

57.002

EPS

0.57

Profit margin

518.033

Employees

175

EBITDA

86M

57M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+140.7% upside

Dividends

By Acuity

Next Earnings

12 lis 2026

Market Stats

By TradingEconomics

Market Cap

-53M

983M

Previous open

17.99

Previous close

17.18

News Sentiment

By Acuity

57%

43%

286 / 340 Ranking in Healthcare

Omeros Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sie 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 sie 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 sie 2026, 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 sie 2026, 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 sie 2026, 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 sie 2026, 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 sie 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 sie 2026, 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 sie 2026, 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 sie 2026, 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 sie 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 lip 2026, 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 lip 2026, 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29 lip 2026, 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28 lip 2026, 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27 lip 2026, 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24 lip 2026, 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22 lip 2026, 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21 lip 2026, 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

20 lip 2026, 19:26 UTC

Omeros Corp shares are higher today, despite an earlier pullback. The stock has stabilized since Friday's close within its one-month trading range.

Peer Comparison

Price change

Omeros Corp Forecast

Price Target

By TipRanks

140.7% upside

12 Months Forecast

Average 33 USD  140.7%

High 33 USD

Low 33 USD

Based on 2 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Sentiment

By Acuity

286 / 340 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat